LigaChem Biosciences begins first patient dosing in the US with solid tumor-targeting ADC 'LCB02A'
Predicted impact: Medium· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)
First US patient dosing of an ADC drug candidate; clinical milestone that can move biotech shares.